Fred Hutchinson Cancer Center

University of California

Blaze Bioscience, Inc.

Roland K Strong

Colin Correnti

Christopher Mehlin

James M Olson

Peter Rupert

Natalie Winblade Nairn

Rebecca J Abergel

Andrew McGuire

Leonidas Stamatatos

Gauthier J P Deblonde

Ilya Captain

Emily June Girard

Andrew David Strand

Thomas Spies

Veronika Spies

Martin Prlic

Mesfin Gewe

Zachary Crook

Gene Gregory Hopping

Chunfeng Yin

Siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity are described. The high affinity siderocalin-metal chelator combinations include a number of chelator backbone arrangements with functional groups that coordinate with metals. The siderocalin-metal chelator combinations can be used to deliver radionuclides for imaging and therapeutic purposes.

Chelating platform for delivery of radionuclides

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Cartilage-homing peptides

Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp120) and can used as an HIV vaccine.

Engineered and multimerized human immunodeficiency virus envelope glycoproteins and uses thereof

Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.

NKG2D decoys

Multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins are multimerized Engineered and multimerized human immunodeficiency virus (HIV) envelope glycoproteins are described. The envelope glycoproteins can be multimerized using a heptamerization domain such as a C4b binding protein multimerization domain or a ferritin fusion. The engineered and multimerized envelope glycoproteins can derived from glycoprotein 120 (gp 120) and can used as an HIV vaccine.

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

Lipocalin fusion partners

Growing community of inventors

Seattle, WA, United States of America

Roland K Strong